Giovanni Martinelli

Giovanni Martinelli

UNVERIFIED PROFILE

Are you Giovanni Martinelli?   Register this Author

Register author
Giovanni Martinelli

Giovanni Martinelli

Publications by authors named "Giovanni Martinelli"

Are you Giovanni Martinelli?   Register this Author

100Publications

3563Reads

35Profile Views

Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer.

J Oncol 2019 19;2019:7475364. Epub 2019 Aug 19.

Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/7475364DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721259PMC
August 2019

Chronic myeloid leukemia stem cells.

Leukemia 2019 Jul 24;33(7):1543-1556. Epub 2019 May 24.

Imperial College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-019-0490-0DOI Listing
July 2019

Aneuploidy: Cancer strength or vulnerability?

Int J Cancer 2019 01 31;144(1):8-25. Epub 2018 Oct 31.

Scientific Directorate, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.31718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587540PMC
January 2019

Novel Agents for Acute Myeloid Leukemia.

Cancers (Basel) 2018 Nov 9;10(11). Epub 2018 Nov 9.

Hematology, Department of Biomedicine and Prevention, "Tor Vergata" University of Rome, 00133 Roma, Italy.

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/10/11/429
Publisher Site
http://dx.doi.org/10.3390/cancers10110429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267447PMC
November 2018

Leukemia cutis in a Ph+ ALL patient treated with ponatinib.

G Ital Dermatol Venereol 2018 Oct;153(5):730-731

Unit of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.17.05647-4DOI Listing
October 2018

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.

Mol Cancer 2018 02 19;17(1):49. Epub 2018 Feb 19.

Hematology/Oncology "L. e A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12943-018-0780-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817796PMC
February 2018

FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage.

J Cell Biochem 2017 11 30;118(11):3968-3975. Epub 2017 May 30.

Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Institute of Hematology L. and A. Seràgnoli-University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.26052DOI Listing
November 2017

Blinatumomab in Ph+ B-ALL: present and perspectives.

Oncotarget 2017 Nov 25;8(55):93309-93310. Epub 2017 Oct 25.

Cristina Papayannidis: Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.22071DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706793PMC
November 2017

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia.

Oncotarget 2017 Oct 22;8(50):88244-88250. Epub 2017 Sep 22.

Department of Experimental Diagnostic and Specialty Medicine, DIMES-Institute of Hematology "L. and A. Seràgnoli", University of Bologna Medical School, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.21166DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675707PMC
October 2017

The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report.

BMC Cancer 2017 Aug 5;17(1):523. Epub 2017 Aug 5.

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Via Massarenti, 9-40138, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3511-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545087PMC
August 2017

Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.

J Clin Oncol 2017 Jun 29;35(17):1905-1912. Epub 2017 Mar 29.

Emanuele Zucca and Franco Cavalli, Oncology Institute of Southern Switzerland, Bellinzona; Luca Mazzucchelli, Cantonal Institute of Pathology, Locarno, Switzerland; Annarita Conconi, Ospedale degli Infermi, Biella; Giovanni Martinelli, European Institute of Oncology; Liliana Devizzi, Fondazione Istituto Nazionale Tumori; Valter Torri, Mario Negri Institute; Andrés J.M. Ferreri, San Raffaele Scientific Institute; Maurilio Ponzoni, San Raffaele Hospital, Milan; Alessandra Tucci, Spedali Civili, Brescia; Umberto Vitolo, University-Hospital Città della Salute e della Scienza, Turin; Maurizio Martelli, Sapienza University; Stefan Hohaus, Catholic University of the Sacred Heart, Rome; Graziella Pinotti, Fondazione Macchi Hospital, Varese; Caterina Stelitano, Bianchi-Melacrino-Morelli Hospitals, Reggio Calabria; Monica Bellei, University of Modena and Reggio Emilia, Modena, Italy; Reda Bouabdallah, Institut Paoli-Calmettes, Marseille; Gilles Salles, Hospices Civils de Lyon and Université Claude Bernard Lyon-1, Pierre-Benite; Catherine Sebban, Centre Léon Bérard, Lyon; Franck Morschhauser, Claude Huriez Hospital, Lille; Anne Moreau, University Hospital of Nantes, Nantes; Hervé Tilly, Centre Henri Becquerel, Rouen; Corinne Haioun, Henri-Mondor Hospital, Paris Créteil; Corinne Haioun, UPEC, Assistance Publique-Hopitaux de Paris; Catherine Thieblemont, Assistance Publique-Hopitaux de Paris, Hôpital-Saint-Louis, Hematooncology-Université Paris Diderot, Sorbonne Paris-Cité, Paris, France; Ruth Pettengell, St George's University of London, London; Andrew Jack, St James's University Hospital, Leeds; Peter Johnson, Southampton General Hospital, Southampton, United Kingdom; Armando Lopez Guillermo and Elias Campo, Hospital Clinic, Barcelona, Spain; Pierre Zachée, ZNA Stuivenberg, Antwerp; and André Bosly, Mont-Godinne UCL, Yvoir, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.6994DOI Listing
June 2017

Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

J Clin Oncol 2017 Jun 29;35(16):1795-1802. Epub 2017 Mar 29.

Giovanni Martinelli and Cristina Papayannidis, Institute of Hematology and Medical Oncology "L. and A. Seràgnoli", Bologna; Alessandro Rambaldi, University of Milan Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; Nicolas Boissel, University Paris Diderot, Hôpital Saint-Louis, Paris; Patrice Chevallier, Centre Hospitalier Universitaire Nantes, Nantes, France; Oliver Ottmann, Cardiff University, Cardiff; Adele K. Fielding, University College London Cancer Institute, London, United Kingdom; Nicola Gökbuget, University Hospital, Goethe University, Frankfurt; Max S. Topp, Universitätsklinikum Würzburg, Würzburg, Germany; Ellen K. Ritchie, Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY; Lulu Ren Sterling, Amgen, San Francisco; Jonathan Benjamin, Amgen, Thousand Oaks; and Anthony Stein, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.3531DOI Listing
June 2017

The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study.

Oncotarget 2017 Jun;8(23):37239-37249

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology 'L. and A. Seràgnoli', University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.16744DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514906PMC
June 2017

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients.

Am J Hematol 2017 Jan 12;92(1):37-41. Epub 2016 Nov 12.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Hematology and Clinical Oncology "L. and A. Seràgnoli", Sant'Orsola-Malpighi University Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24572DOI Listing
January 2017

Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.

Expert Opin Pharmacother 2016 Dec 21;17(18):2479-2486. Epub 2016 Nov 21.

a Institute of Hematology L. e A. Seràgnoli , Universita degli Studi di Bologna Azienda Ospedaliera Sant\'Orsola-Malpighi Ringgold standard institution , Bologna , Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2016.1258056DOI Listing
December 2016

Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia.

Lancet Haematol 2016 12;3(12):e554-e555

University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(16)30170-3DOI Listing
December 2016

P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia.

Front Pharmacol 2016 16;7:491. Epub 2016 Dec 16.

Scientific Direction, IRCCS - Referral Cancer Center of Basilicata Rionero in Vulture (PZ), Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2016.00491DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5159974PMC
December 2016

Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies.

Methods Mol Biol 2016 ;1368:143-59

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology "L. and A. Seràgnoli", University of Bologna, Via Massarenti, 9, Bologna, 40138, Italy.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-3136-1_11
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-3136-1_11DOI Listing
September 2016

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

N Engl J Med 2016 Aug 12;375(8):740-53. Epub 2016 Jun 12.

From the University of Texas MD Anderson Cancer Center, Houston (H.M.K.); the Dana-Farber Cancer Institute, Boston (D.J.D.), and Pfizer, Cambridge (E.V.) - both in Massachusetts; Universitätsklinikum Münster, Münster (M.S.), and Goethe University, Frankfurt (N.G.) - both in Germany; Institute Seràgnoli, DIMES (Department of Experimental, Diagnostic and Specialty Medicine), University of Bologna, Bologna, Italy (G.M.); Stanford Cancer Institute, Stanford (M.L.), and the University of California, Irvine Medical Center, Orange (S.O.) - both in California; the University of Chicago, Chicago (W.S.); Pfizer, Pearl River, NY (K.W.); Pfizer, Groton, CT (T.W., M.L.P., B.S.); and Cleveland Clinic, Cleveland (A.S.A.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5594743PMC
August 2016

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.

J Natl Cancer Inst 2016 Jul 4;108(7). Epub 2016 Mar 4.

Affiliations of authors:Department of Health Policy and Management, Johns Hopkins University , Baltimore, MD (WVP); Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL; Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center , and Cecil G. Sheps Center for Health Services Research, University of North Carolina , Chapel Hill, NC (SBD); Department of Haematology, Hammersmith Hospital, Imperial College , London , UK (JFA); Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany; Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna , Bologna , Italy ; Department of Haematology and Oncology, University Hospital , Jena , Germany (EE); INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG); Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM); Department of Internal Medicine, Hematology and Oncology, University Hospital Brno , Brno , Czech Republic (JM); Department of Hematology and Oncology, University Hospital Leipzig , Leipzig , Germany (DN); Barbara Ann Karmanos Cancer Institute, Wayne State University , Detroit, MI (CAS); Department of Medicine, Weill Cornell Medical Center , New York, NY (RTS); Uppsala University , Uppsala , Sweden (BS).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948567PMC
July 2016

Present and future of molecular monitoring in chronic myeloid leukaemia.

Br J Haematol 2016 05 7;173(3):337-49. Epub 2016 Mar 7.

Department of Experimental, Diagnostic and Specialty Medicine, Haematology/Oncology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13966DOI Listing
May 2016

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.

Oncologist 2016 05 31;21(5):626-33. Epub 2016 Mar 31.

Department of Experimental, Diagnostic and Specialty Medicine, Hematology/Oncology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861357PMC
May 2016

Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities.

Genes Chromosomes Cancer 2016 Apr 27;55(4):375-88. Epub 2016 Jan 27.

Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology and Medical Oncology "Seragnoli," Sant'Orsola-Malpighi Hospital-University, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.22341DOI Listing
April 2016

Adrenomedullin in the growth modulation and differentiation of acute myeloid leukemia cells.

Int J Oncol 2016 Apr 2;48(4):1659-69. Epub 2016 Feb 2.

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2016.3370DOI Listing
April 2016

FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features.

Am J Hematol 2016 Mar;91(3):E14-6

Institute of Hematology and Medical Oncology "Lorenzo E Ariosto Seràgnoli", Sant'Orsola-Malpighi Hospital-University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24276DOI Listing
March 2016

Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03.

J Clin Oncol 2016 Feb 28;34(5):495-500. Epub 2015 Dec 28.

Christian Taverna, Kantonsspital Münsterlingen, Münsterlingen; Felicitas Hitz, Kantonsspital St Gallen, St Gallen; Walter Mingrone, Kantonsspital Aarau/Olten, Olten; Thomas Pabst, Inselspital Bern; Christine Biaggi Rudolf, Stéphanie Rondeau, and Corinne Rusterholz, Swiss Group for Clinical Cancer Research SAKK, Bern; Daniel Rauch, Spital Thun Simmental, Thun; Andreas Lohri, Kantonsspital Liestal, Liestal; Ingmar A.F.M. Heijnen, University Hospital Basel, Basel; Emanuele Zucca and Michele Ghielmini, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Giovanni Martinelli, Anna Vanazzi, and Daniele Laszlo, Istituto Europeo di Oncologia, Milan, Italy; Lidija Cevreska, University Clinic for Hematology, Skopje, Macedonia; Auro del Giglio, ABC Fondation School of Medicine, Sao Paulo, Brazil; Johann Raats, Panorama Oncology Unit, Cape Town; and Daniel A. Vorobiof, Sandton Oncology Center, Johannesburg, South Africa.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.3968DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872010PMC
February 2016

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).

Oncologist 2015 Oct 12;20(10):1149-53. Epub 2015 Aug 12.

Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota USA; Hospital of Bolzano, Department of Hematology & Center of Bone Marrow Transplantation, Bolzano, Italy; Department of Hematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria; University Hospital of Crete, Heraklion, Greece; Athens Medical Center-Psychikon Branch, Athens, Greece; Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Hematology Unit, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Hospital Clínic, Hematology, Barcelona, Spain; Cancer Research UK Centre, Southampton, United Kingdom; Dipartimento Biotecnologie Cellulari ed Ematologia, Universitá La Sapienza, Rome, Italy; European Institute of Oncology, Division of Clinical Haemato-Oncology, Milan, Italy; APHP, Saint-Louis Hospital, Hemato-Oncology, and Diderot University-Sorbonne Paris Cité, Paris, France; Département de Pathologie, Groupe Henri Mondor-Albert Chenevier, AP-HP, Creteil, France; Diagnostic Haematopathology, European Institute of Oncology, Milan, Bologna University School of Medicine, Bologna, Italy; St. James's University Hospital, Leeds, United Kingdom; Hospital Clinic, Anatomia Patologica, IDIBAPS, Barcelona, Spain; ICP Locarno, Locarno, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2015-0180DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591947PMC
October 2015

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.

J Clin Oncol 2015 Oct 17;33(30):3467-74. Epub 2015 Aug 17.

Laurie H. Sehn, Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia; Tara Baetz, Queen's University, Kingston General Hospital, Kingston; Rena Buckstein, Sunnybrook Health Sciences Center; Michael Crump, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; Andre Goy and Luis E. Fayad, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; Fritz C. Offner, Institute of Hematology and Medical Oncology, University of Bologna; Pier Luigi Zinzani, Institute of Hematology "Seràgnoli" University of Bologna, Bologna; Giovanni Martinelli, European Institute of Oncology, Milano; Gianluca Gaidano, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; M. Dolores Caballero, University Hospital of Salamanca, Salamanca, Spain; Ole Gadeberg, Vejle Hospital, Vejle, Denmark; Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, New York; Jonathan Friedberg, James P. Wilmot Cancer Center, University of Rochester, Rochester, NY; Branimir Jadkisic, Clinical Hospital Merkur, University of Zagreb, Zagreb, Croatia; Swaminathan Padmanabhan Iyer, Houston Methodist Cancer Center, Weill Cornell Medical College, Houston, TX; Deniz Sahin and Günter Fingerle-Rowson, Roche, Basel, Switzerland; Akiko Chai, Genentech BioOncology, South San Francisco, CA; Oliver Press, Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.59.2139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087315PMC
October 2015

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

J Clin Oncol 2015 Aug 6;33(23):2523-9. Epub 2015 Jul 6.

Christoph Mamot and Mario Bargetzi, Cantonal Hospital Aarau, Aarau; Dirk Klingbiel, Christine Biaggi, and Corinne Rusterholz, Swiss Group for Clinical Cancer Research Coordinating Center; Thomas Pabst, Inselspital Bern, Bern; Felicitas Hitz and Christoph Driessen, Cantonal Hospital St. Gallen, St. Gallen; Christoph Renner, Hirslanden Zürich; Thomas Hany, Magnetic Resonance Imaging Roentgen Zürich; Andrei Samarin, University Hospital Zürich, Zürich; Ulrich Mey, Cantonal Hospital Graubuenden, Chur; Miklos Pless, Cantonal Hospital Winterthur, Winterthur; Fatime Krasniqi and Stephan Dirnhofer, University Hospital of Basel, Basel; Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; and Federica Gigli and Giovanni Martinelli, European Institute of Oncology Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.9846DOI Listing
August 2015

Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma.

Exp Hematol Oncol 2015 27;4:24. Epub 2015 Aug 27.

Department of Experimental, Diagnostic and Specialty Medicine, DIMES, Institute of Hematology and Medical Oncology L.A. Seragnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40164-015-0019-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4549912PMC
August 2015

Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2015 Jun;15 Suppl:S120-8

Department of Experimental, Diagnostic and Specialty Medicine, Hematology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2015.02.035DOI Listing
June 2015

Treatment of chronic myelogenous leukemia by blocking cytokine alterations found in normal stem and progenitor cells.

Cancer Cell 2015 May;27(5):671-81

Harvard Stem Cell Institute, Harvard Medical School, Boston, MA 02115, USA; Cancer Science Institute, National University of Singapore, Singapore 119077, Singapore. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.04.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4447336PMC
May 2015

Dissecting the role of aberrant DNA methylation in human leukaemia.

Nat Commun 2015 May 22;6:7091. Epub 2015 May 22.

1] Harvard Medical School, Boston, Massachusetts 02115, USA [2] Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts 02138, USA [3] Cancer Science Institute, National University of Singapore, Singapore 66123, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms8091DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443494PMC
May 2015

Interferon in CML: back to the past, or towards the future?

Lancet Haematol 2015 Jan 7;2(1):e8-9. Epub 2015 Jan 7.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Unit of Hematology, University of Bologna, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S2352-3026(14)00038-6DOI Listing
January 2015